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Daily emollient during infancy for prevention of eczema: 
the BEEP randomised controlled trial
Joanne R Chalmers, Rachel H Haines, Lucy E Bradshaw, Alan A Montgomery, Kim S Thomas, Sara J Brown, Matthew J Ridd, Sandra Lawton, 
Eric L Simpson, Michael J Cork, Tracey H Sach, Carsten Flohr, Eleanor J Mitchell, Richard Swinden, Stella Tarr, Susan Davies-Jones, Nicola Jay, 
Maeve M Kelleher, Michael R Perkin, Robert J Boyle, Hywel C Williams on behalf of the BEEP study team
Summary
Background Skin barrier dysfunction precedes eczema development. We tested whether daily use of emollient in the 
first year could prevent eczema in high-risk children.
Methods We did a multicentre, pragmatic, parallel-group, randomised controlled trial in 12 hospitals and four primary 
care sites across the UK. Families were approached via antenatal or postnatal services for recruitment of term infants 
(at least 37 weeks’ gestation) at high risk of developing eczema (ie, at least one first-degree relative with parent-
reported eczema, allergic rhinitis, or asthma, diagnosed by a doctor). Term newborns with a family history of atopic 
disease were randomly assigned (1:1) to application of emollient daily (either Diprobase cream or DoubleBase gel) for 
the first year plus standard skin-care advice (emollient group) or standard skin-care advice only (control group). The 
randomisation schedule was created using computer-generated code (stratified by recruiting centre and number of 
first-degree relatives with atopic disease) and participants were assigned to groups using an internet-based 
randomisation system. The primary outcome was eczema at age 2 years (defined by UK working party criteria) with 
analysis as randomised regardless of adherence to allocation for participants with outcome data collected, and 
adjusting for stratification variables. This trial is registered with ISRCTN, ISRCTN21528841. Data collection for long-
term follow-up is ongoing, but the trial is closed to recruitment.
Findings 1394 newborns were randomly assigned to study groups between Nov 19, 2014, and Nov 18, 2016; 693 were 
assigned to the emollient group and 701 to the control group. Adherence in the emollient group was 88% (466 of 532) 
at 3 months, 82% (427 of 519) at 6 months, and 74% (375 of 506) at 12 months in those with complete questionnaire 
data. At age 2 years, eczema was present in 139 (23%) of 598 infants with outcome data collected in the emollient 
group and 150 (25%) of 612 infants in the control group (adjusted relative risk 0·95 [95% CI 0·78 to 1·16], p=0·61; 
adjusted risk difference –1·2% [–5·9 to 3·6]). Other eczema definitions supported the results of the primary analysis. 
Mean number of skin infections per child in year 1 was 0·23 (SD 0·68) in the emollient group versus 0·15 (0·46) in 
the control group; adjusted incidence rate ratio 1·55 (95% CI 1·15 to 2·09).
Interpretation We found no evidence that daily emollient during the first year of life prevents eczema in high-risk 
children and some evidence to suggest an increased risk of skin infections. Our study shows that families with 
eczema, asthma, or allergic rhinitis should not use daily emollients to try and prevent eczema in their newborn.
Funding National Institute for Health Research Health Technology Assessment.
Copyright © 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 
license.
Introduction
Eczema (additionally termed atopic dermatitis or atopic 
eczema) affects about one in five children,1 is increasing 
in prevalence, and confers a high disease burden for 
individuals and their carers.2 Eczema usually starts in 
infancy, and persistence into adulthood is common.3 
Children with eczema are more likely to develop other 
atopic conditions including food allergies, asthma, and 
allergic rhinitis.4 Because eczema usually precedes the 
development of food allergy, and early onset eczema is 
strongly associated with food allergy, prevention of 
eczema could prevent the development of food allergy.5,6
Eczema is associated with loss-of-function mutations 
in FLG, the gene encoding filaggrin—a multi-functional 
protein that contributes to skin barrier integrity.7 This 
suggests that an impaired skin barrier could be a key 
defect in eczema development.7,8 Sensitisation to food 
allergens can occur via a defective skin barrier.9–14 Several 
observations support the rationale for emollients as a 
primary prevention intervention for eczema. Skin barrier 
dysfunction is apparent soon after birth and precedes 
eczema development, providing an opportunity for 
strategies to improve skin hydration and barrier 
function.15,16 Emollients render the skin less susceptible 
to irritants such as soaps and detergents that could 
initiate eczema, can reduce percutaneous sensitisation 
by food antigens,8,15 and can prevent flares of eczema 
(secondary prevention).17 Two small randomised pilot 
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trials provided evidence that eczema prevention through 
emollients might be possible.13,14 One study13 of 124 infants 
at high risk of eczema born in the UK and the USA 
showed that 22% of infants advised to use daily 
emollients developed eczema by age 6 months compared 
with 43% in controls (relative risk [RR] 0·50, 95% CI 
0·28–0·90). The second study14 included 118 high-risk 
infants in Japan and showed that 32% of infants in the 
intervention group had eczema after 32 weeks versus 
47% in the control group (hazard ratio 0·48, 95% CI 
0·27–0·86). These strong efficacy signals from two small 
studies underpinned the decision of our funders to 
support a large-scale pragmatic trial to assess whether 
this intervention was effective when tested in normal 
practice.
Simple emollient formulations are inexpensive, widely 
available, and used extensively for treating eczema, and if 
effective in preventing eczema, could represent a 
breakthrough in reducing eczema incidence globally. 
We undertook this large, pragmatic trial to test the 
hypothesis that emollient use in the first year of life in 
high-risk infants (ie, with a family history of atopic 
disease) can prevent eczema and other atopic diseases 
including food allergy.
Methods
Study design and participants
This was a multicentre, two-arm, parallel-group, 
randomised controlled trial that was done at 12 hospitals 
and four primary care sites across the UK (appendix p 3). 
Families were approached largely via antenatal or 
postnatal services, by invitation letters from their general 
practitioners (GP), and through posters describing the 
study in hospitals and the community. Term infants 
(at least 37 weeks’ gestation) at high risk of developing 
eczema (ie, at least one first-degree relative with parent-
reported eczema, allergic rhinitis, or asthma diagnosed 
by a doctor) were included. Other inclusion criteria were 
mother aged 16 years or older, and the consenting adult 
had to have the ability to understand English. Exclusion 
criteria were as follows: preterm birth (birth before 
37 weeks’ gestation); a sibling (including twin) randomly 
assigned in the trial; a severe widespread skin condition 
that would make detection or assessment of eczema 
difficult; a serious health issue that would make it 
difficult for the family to take part in the trial; and a 
condition that would make the use of emollient 
inadvisable. Screening was usually done during the 
third trimester or shortly after delivery, and most 
Research in context
Evidence before this study 
Genetic discoveries suggest that enhancing the skin barrier from 
birth might prevent eczema. In 2014, our pilot trial of 
124 infants born to high-risk families suggested that daily 
emollients used for 6 months after birth could reduce 
development of eczema by around 50%. A similar study of 
118 neonates in Japan found similar results with a 32% reduction 
in eczema at 32 weeks. We therefore designed the barrier
enhancement for eczema prevention (BEEP) study to determine 
the effectiveness of advice to use emollients daily for the first 
year of life to prevent eczema in infants born to high-risk 
families. We searched the Centre of Evidence-Based Dermatology 
maps of systemic reviews of eczema prevention and Cochrane 
Central Register of Controlled Trials, MEDLINE, and online trial 
registries from Jan 1, 2000, until Aug 25, 2019, with no language 
restrictions, using synonyms for trials: ‘‘randomized controlled 
trial’’, ‘‘controlled clinical trial’’, ‘‘randomized’’, ‘‘placebo’’, 
‘‘randomly’’, ‘‘trial’’; and for eczema: “dermatitis” or “eczema” or 
“neurodermatitis” or “besnier” and “prevention”.
We found 102 systematic reviews on eczema prevention but none 
dealing with barrier enhancement. Two randomised controlled 
trials of emollients for prevention of eczema have been published 
since our search: one from Japan including 459 infants (which 
tested Locobase REPAIR cream, Daiichi Sankyo, Japan) and the 
second from the USA including 100 infants (which tested Cetaphil 
Restoraderm, Galderma Laboratories, TX, USA). These two studies 
used ceramide-containing emollients, neither of which showed 
any significant preventive effect against development of eczema. 
Several additional ongoing trials investigating skin barrier 
interventions for eczema prevention have been identified, one of 
which (PreventADALL) is reported in this issue.
Added value of this study 
The BEEP study of 1394 infants, the first large randomised 
controlled trial to specifically investigate whether emollients 
could prevent eczema, found no evidence to support the 
hypothesis that advice to use daily emollients can prevent 
eczema (primary outcome), food allergy, sensitisation, allergic 
rhinitis, or wheezing (secondary outcomes), and some evidence 
to suggest an increase in skin infections in those using 
emollients. Given the demanding nature of asking parents to 
apply emollients to the whole body for 12 months, we were 
pleased with reported adherence proportions of 88%, 82%, 
and 74% at 3 months, 6 months, and 12 months respectively.
Implications of all the available evidence
Since the publication of the two small efficacy studies, health-
care professionals have started to recommend emollient for the 
primary prevention of eczema in high-risk families. This large, 
pragmatic study suggests that emollients used in this way do 
not prevent eczema and might be associated with harm, and 
that such practices should be stopped unless new evidence 
suggests otherwise. Knowledge of the neonatal skin barrier and 
optimal emollient formulation has progressed since the BEEP 
study was initiated, so new products might potentially exert a 
protective effect, which could be enhanced if accompanied by 
additional measures such as soft water and avoidance of soap.
See Online for appendix
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families chose for this screening to take place in the 
family home.
Informed consent was obtained from mothers during 
pregnancy, or from the mother, father, or guardian after 
delivery. The trial was overseen by an independent Trial 
Steering Committee (appendix p3) and approved by the 
West Midlands Ethics Committee, UK (14/WM/0162). 
The study was sponsored by the University of Nottingham, 
coordinated by the Nottingham Clinical Trials Unit 
(CTU), and funded by the UK National Institute for 
Health Research (NIHR) Health Technology Assessment 
Programme. Supplementary funding was obtained for 
inclusion of food allergy outcomes and skin prick tests 
subsequent to study initiation, which was provided by 
Goldman Sachs Gives and Sheffield Children’s Hospital 
Charity. The full protocol and changes made after the 
trial started are available online on the trial website and in 
the appendix (p 10). A protocol summary was published 
previously.18
Randomisation and masking
Infants were randomly assigned (1:1) to receive either 
emollient and best practice skin-care advice (emollient 
group) or best practice skin-care advice only (control 
group). Infants were randomly assigned to a group within 
a maximum of 21 days after delivery, and randomisation 
was stratified by recruiting centre and number of first-
degree relatives with atopic disease (1, 2, or >2). The 
randomisation schedule was created by the CTU using 
computer-generated pseudo-random code with permuted 
blocks of randomly varying size. The sequence was known 
only to the programmer until database lock. Research 
nurses randomly assigned participants to groups using a 
secure, internet-based randomisation system developed 
and maintained by the CTU. Parents were informed of 
their child’s allocation by staff at the CTU. Research 
nurses doing skin examinations, skin prick testing, food 
challenges, or making food allergy decisions, and the 
statistician, were masked to treatment allocation during 
the study. Interim follow-up at 2 weeks and at 3, 6, 12, and 
18 months was done by CTU staff to maintain research 
nurse masking. Participating families were not masked.
Procedures
Families in the intervention group could choose between 
Doublebase Gel (Dermal Laboratories, Herts, UK) or 
Diprobase Cream (Bayer, Berks, UK). They were sent an 
initial package containing both emollients and parents 
specified on their resupply instructions which of the 
two emollients they wished to receive. Parents were 
advised to apply emollient to their child at least once 
daily to the whole body (excluding the scalp) until the 
child reached 1 year of age. They were also advised to 
apply emollient after every bath, even if they had already 
applied the emollient that day. Daily application was 
advised to encourage regular use of emollient several 
times a week, but because the study was designed to 
reflect how the intervention might be delivered in normal 
practice, no prompts or reminders were sent to parents.
Parents were advised to stop applying emollients when 
their child reached 1 year of age, and no further 
emollients were supplied after this point.
Both groups received advice on general skin care in 
booklet and video format at the time of randomisation 
(appendix pp 11–21). The skin care guidance provided 
advice to use mild cleansers and shampoos specifically 
formulated for infants, and to avoid soap, bubble bath, 
and baby wipes.19 The guidance given to those in the 
emollient group also showed parents how to apply 
emollients correctly by dotting over the skin and using 
gentle downward strokes rather than rubbing in and 
contained warnings about the skin being slippery after 
application and the need to clean up spillages from the 
floor to avoid slipping. Parents were advised to seek 
medical advice as they would normally do if their child 
developed skin problems.
Follow-up was at 2 weeks (by telephone) and at 3, 6, 12, 
and 18 months (online or postal questionnaire). At the 
2-year follow-up visit, the masked research nurse did the 
skin examination, saliva sample collection, skin prick 
testing, and provided the questionnaires, usually in the 
family home. In cases for whom a visit was not possible, 
data were collected by telephone, email, SMS, postal 
questionnaire, or from the GP. Methods for saliva 
collection, DNA extraction, and skin prick testing were 
published previously.18,20 DNA samples were genotyped 
for the four most common FLG null mutations in the 
white European population (2282del4, R501X, S3247X, 
and R2447X).21 Participants who had a positive skin-prick 
test or a history suggestive of food allergy and in whom 
further investigation was required for a diagnosis of food 
allergy to be made were invited for a supervised oral food 
challenge. Food challenges were done at two hospitals 
by experienced allergy nurses masked to treatment 
allocation, following standard procedures.
Outcomes
The primary outcome was diagnosis of eczema over the 
past year (defined by the UK working party refinement of 
the Hanifin and Rajka diagnostic criteria for eczema) 
assessed by research nurses masked to treatment 
allocation at age 2 years.22 This timepoint of 1 year after 
the intervention ended was chosen to ensure that the 
emollient had a genuine and lasting protective effect on 
eczema incidence as opposed to masking the emergence 
of mild eczema that might have occurred because of 
emollient use during year 1.23,24
Secondary eczema outcomes were other eczema 
definitions—ie, presence of eczema between birth and 
2 years of age (assessed by any parental report of a clinical 
diagnosis of eczema [up to 2 years] and parent completion 
of UK working party criteria at 1 and 2 years), presence of 
visible eczema at 2 years recorded by a nurse who was 
masked to treatment allocation; time to onset of eczema 
For more on the BEEP study see 
https://www.nottingham.ac.uk/
research/groups/cebd/
projects/1eczema/beep-
maintrial.aspx
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(based on first parent report of clinician diagnosis and 
time of first topical corticosteroid or immunosuppressant 
prescription); clinician-reported and patient-reported 
severity of eczema (Eczema Area and Severity Index [EASI] 
at 2 years and Patient-Oriented Eczema Measure [POEM] 
at 1 and 2 years). Other secondary outcomes were presence 
of other allergic diseases (ie, parent-reported wheezing 
and allergic rhinitis [between 1 and 2 years]; allergic 
sensitisation [masked skin prick tests] to milk, egg, peanut, 
cat dander, grass pollen, or dust mite at 2 years; parent-
reported food allergy and parental report of clinical 
diagnosis of food allergy at 1 and 2 years; and allergy 
to milk, egg, or peanut at 2 years confirmed either by oral 
food challenge or for cases in which no oral food challenge 
was done, an expert allergy panel masked to treatment 
allocation). The expert panel decisions were made using a 
validated algorithm adapted from the EAT trial, which 
incorporates all available data including skin-prick test 
results, previous reaction history, frequency of food 
ingestion, and allergy tests done outside the trial.25 Safety 
outcomes were parent-reported skin infections (parents 
were asked what the doctor called the infection) and 
emollient-related infant slippages during the intervention 
period (year 1).
Analysis of health economic outcomes is underway and 
will be published separately. This will include analysis of 
health-care resource use at 3, 6, 12, 18, and 24 months, and 
cost-effectiveness and cost–utility at 24 months.
Figure 1: Trial profile
*One family was randomly assigned in error at 62 days after birth and so was not included further. The family was not informed of the randomisation, not sent any 
intervention, and was not contacted for any follow-up. †A sensitivity analysis including all participants was also done using multiple imputation for missing data.
4963 families potentially eligible
1484 families consented
3479 excluded
 2057 families declined to participate
 826 initially expressed interest but were unable to be contacted
 458 did not meet inclusion criteria
 94 recruitment had closed
 44 other reasons
693 randomly assigned to the intervention group
 (emollient and best practice infant skin care advice)
94 lost to follow-up
 55 no response
 39 parent or main carer withdrew consent
701 randomly assigned to the control group
 (best practice infant skin care advice only)
599 completed the 24-month follow-up visit
 555 face to face
 44 by telephone, email, SMS, or post
613 completed the 24-month follow-up visit
 568 face to face
 45 by telephone, email, SMS, or post
1394 babies randomly assigned
89 families not randomly assigned
 50 no longer eligible
 20 withdrew consent
 9 lost to follow-up
 1 infant death
 2 randomisation had closed
 7 other
 1 baby randomly assigned in error 62 days after birth*
88 lost to follow-up
 58 no response
 29 parent or main carer withdrew consent
 1 other (no time)
1 with insufficient data collected to derive primary outcome 
598 included in primary analysis† 612 included in primary analysis†
1 with insufficient data collected to derive primary outcome
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Quality of life was measured by Child Health Utility 
(CHU-9D) at 2 years to estimate quality-adjusted life-years 
(QALYs) in infants, and by EQ-5D-5L for parents at 
baseline and 2 years to estimate parental QALYs.
Adherence was captured at each questionnaire 
timepoint during year 1 (3, 6, and 12 months) by asking 
parents about emollient use since the last questionnaire 
(appendix p 4), and was defined in the protocol as 
satisfactory in the intervention group if emollients were 
applied at least 3–4 times per week to most of the child’s 
body (defined as at least two of face and neck, arms 
and legs, or trunk). A similar definition was used for 
contamination in the control group.
Analysis and publication of data for the 2-year primary 
outcome timepoint were preplanned. Data collection for 
long-term outcomes at 3, 4, and 5 years is ongoing, but 
the trial is closed to recruitment of new participants.
Statistical analysis
The trial was designed to detect a relative reduction of 
30% in eczema at the 5% significance level (two-sided) 
with 90% power based on an expected rate of eczema of 
30% in the control group and 20% attrition, resulting in a 
sample size of 1282.18 Quicker than expected recruitment 
prompted a review by the Trial Steering Committee 
(August, 2016), who permitted all pregnant mothers who 
had already given consent by that point to be randomly 
assigned to a study group upon the birth of the baby, 
allowing for a maximum recruitment total of 1400.
We analysed participants as randomised regardless of 
adherence with allocation and using observed data. The 
adjusted RR and difference in risk for the primary outcome 
were estimated using Generalised Estimating Equations 
with the Binomial family and log/identity link respectively, 
with an exchangeable correlation matrix to account for 
randomisation being stratified by centre and number of 
immediate family members with atopic disease (1, 2, or 
>2) included as a covariate. Sensitivity analyses were done 
using multiple imputation for missing data to include all 
participants in the analysis, split according to method of 
data collection (in person or by telephone, email, SMS, or 
post) and actual emollient use (complier average causal 
effect [CACE] accounting for emollient use in both 
groups). Analyses of secondary and safety outcomes 
used appropriate regression models and adjusted for 
stratification variables. Subgroup analyses for the primary 
outcome (diagnosis of eczema) and the secondary outcome 
of confirmed food allergy were done by including an 
interaction term in the analysis model for FLG genotype, 
number of first-degree relatives with atopic disease, and 
number of first-degree relatives with eczema. Additional 
subgroup analyses for the primary outcome for season of 
birth, water hardness in the home, and parent-reported 
probiotic supplements during pregnancy were in the 
statistical analysis plan (SAP) but not the protocol. Further 
details are presented in the appendix and SAP, finalised 
before the database lock. Analyses were done with Stata 
version 15.1. The trial was registered at the ISRCTN 
registry before initiation of recruitment, ISRCTN21528841.
Role of the funding source
The main funder (NIHR Health Technology Assess-
ment) was involved in refining the trial design through 
the funding peer review process, but had no role in data 
collection, data analysis, data interpretation, or writing 
of the report. The funders of the food allergy outcomes 
and skin prick tests (Goldman Sachs Gives and Sheffield 
Children’s Hospital Research Fund) had no role in the 
study design, data collection, data analysis, data inter-
pretation, or writing of the manuscript. HCW, AAM, 
and LEB had full access to all the data in the study, and 
For the statistical analysis plan 
see https://www.nottingham.
ac.uk/research/groups/cebd/
documents/researchdocs/0935-
beep-sap-final-v1.0-20181205-
signed.pdf
Emollient group
(n=693)
Control group
(n=701)
Age of mother at randomisation (mean [SD]) 31·7 (5·3) 31·5 (5·2)
Parental-reported number of first-degree relatives with atopic disease
1 254 (37%) 253 (36%)
2 300 (43%) 296 (42%)
3 or more 139 (20%) 152 (22%)
At least one first-degree relative with history of eczema 
(parent report of doctor diagnosis)
563 (81%) 580 (83%)
Mother has eczema or had a history of eczema (parent report 
of doctor diagnosis)
348 (50%) 372 (53%)
Singleton pregnancy* 690 (100%) 696 (99%)
Gestation at birth in weeks (median [IQR]) 40 [39·1–40·9] 40 [39·0–40·9]
Ethnicity of mother
White 589 (85%) 601 (86%)
Asian 45 (6%) 40 (6%)
Black 31 (4%) 22 (3%)
Other 28 (4%) 38 (5%)
Decile of English index of multiple deprivation 2015 (median 
[IQR])
6 (3–9) 6 (3–8)
No other children living in household at screening 275 (40%) 293 (42%)
Sex
Male infant 374 (54%) 359 (51%)
Female infant 319 (46%) 342 (49%)
Vaginal delivery 482 (70%) 472 (67%)
Furry pets living in house at time of birth 295 (43%) 302 (43%)
Maternal antibiotics during pregnancy 210 (30%) 201 (29%)
Maternal probiotics during pregnancy (collected at 
6 months)
33/511 (6%) 32/505 (6%)
FLG genotyping†
Number of infants 402 414
+/+ (no mutations) 339/402 (84%) 352/414 (85%)
+/– (one FLG null mutation) 62/402 (15%) 60/414 (14%)
–/– (two FLG null mutations) 1/402 (<1%) 2/414 (<1%)
Data presented are n (%) or n/N (%) unless otherwise specified. FLG=gene encoding filaggrin. *Three cases in the 
emollient group and five cases in the control group  were twin and higher-order pregnancies. †FLG genotype obtained 
from saliva samples at 2-year visit for infants whose parents consented to this part of the study. Samples were tested for 
the four most prevalent FLG loss-of-function mutations in the white European population. Of the 816 children included 
in the analysis, 810 (400 in the emollient group and 410 in the control group) had both parents of white ethnicity and 
six (two in the emillient group and four in the control group) had parents not of white ethnicity, but were included in 
the analysis because an FLG null mutation was detected.
Table 1: Baseline characteristics
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HCW had final responsibility for the decision to submit 
for publication.
Results
Between Nov 19, 2014, and Nov 18, 2016, 4963 families 
were assessed for eligibility at 12 hospitals and four 
general practice sites in the UK. 1394 babies were 
randomly assigned (1:1) to study groups (693 to the 
emollient group and 701 to the control group; figure 1). 
Baseline characteristics were balanced across groups 
(table 1). Accidental unmasking of outcome assessors to 
treatment allocation occurred for 3% of families at the 
2-year visits (41 of 1190 participants who completed 
follow-up in person, or via telephone, text, or email; 
30 in the emollient group and 11 in the control group). 
509 families in the emollient group responded to a 
telephone call to check they had received the skin-care 
pack and emollients, and to collect data on the date they 
started applying the emollient to the infant. The median 
age of those in the emollient group when starting emol-
lient was 11 days (IQR 7–17; n=509), and 452 (89%) of 
509 had started applying emollient by day 21. Of families 
in the emollient group with complete questionnaire data 
on adherence at each timepoint, 466 (88%) of 532 had 
satisfactory adherence at 3 months, 427 (82%) of 519 at 
6 months, and 375 (74%) of 506 at 12 months. 70% (311 of 
442) of families with complete question naire data were 
classed as having satisfactory adherence at all time points 
during the first year. Using a highly conservative estimate 
that assumed 100% of those with no questionnaire data 
on adherence (ie, did not complete the questionnaires at 
3, 6, or 12 months) did not apply the emollient, the 
proportion of families in the emollient group classed as 
having satisfactory adherence was estimated to be 51% 
(appendix p 32). On the days families used the interven-
tion, most families chose to apply the emollient once a 
day (422 [79%] of 532 families at 3 months, 382 [74%] of 
517 at 6 months, and 362 [72%] of 506 at 12 months). 
93 (17%) of 532 families at 3 months, 104 (20%) of 
517 families at 6 months, and 94 (19%) of 506 at 12 months 
chose to apply the emollient twice a day or more. Most 
participating families, with 479 (90%) of 533 at 3 months, 
460 (89%) of 519 at 6 months, and 425 (84%) of 508 at 
12 months, applied emollient to the arms, legs, and 
trunk. Additionally, most reported they usually applied 
emollient after a bath: 89% (471 of 532) at 3 months, 
85% (441 of 516) at 6 months, and 80% (406 of 508) at 
12 months. A median of 5 (IQR 2–5) 500 g containers 
dispensed over the year equated to about 7 g emollient 
per day over the first year. No emollient was supplied to 
the control group, but self-directed use of emollients 
at least three times per week to most of the body 
(contamination) occurred in 18% (82 of 457) at 3 months, 
17% (62 of 372) at 6 months, and 15% (49 of 324) at 
12 months, excluding children with a parental reported 
doctor diagnosis of eczema and who were therefore 
likely to be using an emollient to treat their eczema 
(appendix p 31).
Most infants in both groups were bathed or showered 
at least every other day (6 months, 81% of emollient 
group and 78% of control group; 12 months, 87% of 
emollient group and 87% of control group; 24 months, 
90% of emollient group and 91% of control group). 
A third of participating families (32% of emollient 
group, 31% of control group) used water only (up to 
6 months) and half used baby-specific wash products 
during the first year. Washing practices were balanced 
across groups (appendix pp 35–36).
Emollient group Control group Adjusted relative 
risk (95% CI)
Adjusted difference 
in risk (95% CI)
Diagnosis of eczema at age 2 years according to UK working party 
diagnostic criteria*
139/598 (23%) 150/612 (25%) 0·95 (0·78 to 1·16) –1·2% (–5·9 to 3·6)
Secondary eczema outcomes
At age 2 years
Masked assessment of visible eczema at age 2 years 151/555 (27%) 149/568 (26%) 1·05 (0·86 to 1·27) 1·1% (–4·0 to 6·3)
Parent report of a clinical diagnosis of eczema between birth 
and age 2 years
266/610 (44%) 282/616 (46%) 0·96 (0·85 to 1·08) –2·0% (–7·5 to 3·6)
Eczema according to UK working party diagnostic criteria 
(parent completion)
187/599 (31%) 195/612 (32%) 0·98 (0·83 to 1·16) –0·5% (–5·7 to 4·8)
Moderate, severe, or very severe eczema according to EASI 9/553 (2%) 10/567 (2%) 0·93 (0·38 to 2·27) 0·0% (–1·5 to 1·4)
Moderate, severe, or very severe according to POEM 58/576 (10%) 51/595 (9%) 1·18 (0·82 to 1·68) 1·7% (–1·6 to 5·0)
At age 1 year
Eczema according to UK working party diagnostic criteria 
(parent completion)
103/516 (20%) 107/527 (20%) 0·98 (0·77 to 1·25) –0·3% (–5·1 to 4·6)
Moderate, severe, or very severe according to POEM 52/512 (10%) 49/522 (9%) 1·09 (0·75 to 1·57) 1·0% (–2·5 to 4·6)
Data are n/N (%) unless otherwise specified. The adjusted relative risk and difference in risk are estimated using generalised estimating equations with the binomial family 
and log/identity link respectively, with an exchangeable correlation matrix to account for randomisation being stratified by centre and number of immediate family members 
with atopic disease (1, 2, or more than 2) included as a covariate. EASI=Eczema Area and Severity Index. POEM=Patient-Oriented Eczema Measure. *p=0·61.
Table 2: Primary and secondary eczema outcomes
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Eczema in the past 12 months (UK working party 
criteria) at age 2 years was present in 139 (23%) of 
598 infants in the emollient group and in 150 (25%) of 
612 in the control group (adjusted RR 0·95 [95% CI 
0·78 to 1·16]; p=0·61; adjusted risk difference –1·2% [–5·9 
to 3·6]; table 2). Sensitivity analyses were consistent with 
the primary analysis, by use of data from GP records for 
missing primary outcome data, imputed missing data, and 
CACE analysis to evaluate adherence (appendix pp 40–42). 
Subgroup analyses according to number of first-degree 
relatives with atopic disease or eczema, FLG genotype, 
season of birth, water hardness, and probiotic use found 
no evidence of an interaction (appendix pp 42, 44–45).
All other measures of eczema diagnosis were consistent 
with the primary outcome. There were no differences 
between groups in visible eczema at 2 years, parent report 
of a clinical diagnosis of eczema at 2 years, or parent 
completion of UK working party criteria at 1 and 2 years 
(table 2). Eczema severity assessed either by a masked 
assessment of clinician-reported signs (EASI)26 or parent-
reported symptoms (POEM)27 was also similar between 
groups (figure 2), as was time to onset of eczema (appendix 
pp 47–50). Food allergies to milk, egg, or peanut were 
confirmed in 41 (7%) of 547 infants in the emollient group 
and 29 (5%) of 568 in the control group (adjusted RR 1·47, 
95% CI 0·93–2·33). The largest difference was in the 
proportion of infants with confirmed food allergy to egg, 
with an adjusted RR of 1·56 (95% CI 0·92–2·65). Of the 
confirmed food allergy diagnoses, 30% (21 of 70; 15 in the 
emollient group and six in the control group) were made 
with the oral food challenge and 70% (49 of 70; 26 in the 
emollient group and 23 in the control group) were by use 
of the algorithm adapted from the EAT trial.25 The results 
of other measures of food allergy and food sensitisation 
were similar (appendix pp 59–61). The proportion of 
infants with allergic rhinitis, wheezing, and allergic 
sensitisation to cat dander, grass pollen, and dust mite 
was similar between groups (table 3). There were no 
differences in quality of life utility measures (CHU-9D 
and EQ-5D-5L) between the two groups (table 4).
Parent-reported doctor-diagnosed skin infections 
during the first year occurred in 89 (15%) of 585 infants 
in the emollient group and in 67 (11%) of 589 in the 
control group. Impetigo and unspecified bacterial, viral, 
or fungal skin infections accounted for the majority 
and a full breakdown of the type of infection can be 
found in the appendix (p 62). The mean number of skin 
infections per child was 0·23 (SD 0·68) in the emollient 
group and 0·15 (0·46) in the control group (adjusted 
incidence rate ratio of 1·55, 95% CI 1·15–2·09; 
appendix p 62). Parent-reported infant slippages within 
an hour of applying emollients were rare and the 
frequency was similar between groups: 15 (3%) of 
584 in the emollient group and 11 (2%) of 584 in the 
control group (adjusted RR 1·37, 95% CI 0·63–2·97). 
None of the slippages resulted in serious injury or 
admission to hospital.
Discussion
In this multicentre, pragmatic, randomised controlled 
trial of high-risk infants, we did not find any evidence 
that regular emollient use for the first year of life can 
delay, suppress, or prevent eczema at age 2 years. The 
results for the primary outcome excluded our prespecified 
relative reduction of 30%. This finding was consistent 
regardless of how eczema was defined. There was no 
Figure 2: Severity of eczema assessed by clinician-reported signs measured 
by EASI (masked assessment) and parent-reported symptoms measured by 
POEM
(A) Severity at 2 years measured by EASI (masked assessment by research nurse) 
based on categories in Leshem and colleagues.26 Parent-reported severity at 
1 year (B) and 2 years (C) measured by POEM, based on categories in Charman 
and colleagues.27 These analyses include all infants for whom data were available, 
regardless of their eczema status. EASI=Eczema Area and Severity Index. 
POEM=Patient-Oriented Eczema Measure.
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evidence that emollients reduced the risk of food allergy; 
a non-significant increase in food allergy in the emollient 
group was observed compared with controls. This was 
largely because of the higher number of participants in 
the emollient group being diagnosed with egg allergy. 
Furthermore, we observed an increase in parent-reported 
skin infections. Notably, we emphasise that our findings 
relate only to using emollients for preventing eczema, 
and not the use of emollients for treating eczema.
Strengths of this study include the large sample size 
and good rates of treatment adherence, high retention 
for the primary outcome, and low rates of contamination, 
particularly given that it was a long-term prevention 
study of healthy infants with little investigator contact. 
Our study tested an intervention that was acceptable 
to parents and the use of emollients in the study is 
likely to closely reflect how emollients are recommended 
and used in the community.28 Selection, detection, 
performance, and attrition biases are unlikely to explain 
the absence of a preventive effect. Eczema was measured 
using validated criteria, applied by trained researchers 
masked to the treatment intervention 1 year after use of 
the emollient had ceased. The primary outcome results 
were collected by masked researchers, although the 
diagnostic criteria do include questions that are answered 
by unmasked parents. Findings were supported by a 
masked evaluation of eczema that did not rely on parent 
reporting. Assessing the primary outcome at age 2 years 
excludes transient eczematous rashes that are common 
in the first year of life and ensures that any eczema 
present is not concealed by the application of emollient 
during the first year—issues that might have accounted 
for the protective effect of emollients seen in the 
two previous smaller pilot studies.
The study emollients were chosen because they are 
commonly used in the UK National Health Service and 
have a high degree of acceptability to parents, established 
during preparatory work. Both emollients are a basic 
formulation containing petrolatum and no ingredients 
known to have a detrimental effect on the skin barrier, in 
particular sodium lauryl sulphate. Mechanistic studies 
showed that these emollients were appropriate to use in 
such a trial, compared with aqueous cream, which has 
adverse effects on the skin barrier if used as a leave-on 
emollient.29,30 We did not use a more complex emollient 
Emollient group Control group Adjusted relative 
risk (95% CI)
Adjusted difference in 
risk (95% CI)
Confirmed food allergy 
Confirmed allergy to milk, egg, or peanut at age 2 years* 41/547 (7%) 29/568 (5%) 1·47 (0·93 to 2·33) 2·4% (–0·5 to 5·2)
Confirmed allergy to cow’s milk at age 2 years†  9/571 (2%) 8/593 (1%) 1·17 (0·45 to 3·01) 0·2% (–1·2 to 1·6)
Confirmed allergy to egg at age 2 years 33/560 (6%) 22/581 (4%) 1·56 (0·92 to 2·65) 2·1% (–0·4 to 4·6)
Confirmed allergy to peanut at age 2 years 10/555 (2%) 8/572 (1%) 1·29 (0·51 to 3·25) 0·4% (–1·1 to 1·8)
Sensitisation to food allergens‡§
Allergic sensitisation to milk, egg, or peanut at age 2 years 58/487 (12%) 44/498 (9%) 1·36 (0·94 to 1·95) 2·9% (–0·9 to 6·8)
Allergic sensitisation to milk at age 2 years 14/488 (3%) 11/498 (2%) ·· ··
Allergic sensitisation to egg at age 2 years 43/490 (9%) 33/499 (7%) ·· ··
Allergic sensitisation to peanut at age 2 years 18/490 (4%) 16/502 (3%) ·· ··
Sensitisation to other allergens
Allergic sensitisation to grass pollen, cat dander, or dust mite 
at age 2 years¶
50/492 (10%) 48/499 (10%) 1·07 (0·74 to 1·55) 0·9% (–2·8 to 4·5)
Other allergies
Allergic rhinitis, parent report between age 1 and 2 years 174/572 (30%) 188/598 (31%) 0·97 (0·82 to 1·15) –0·8% (–6·2 to 4·5)
Wheezing, parent report between age 1 and 2 years 197/572 (34%) 191/598 (32%) 1·07 (0·91 to 1·26) 2·5% (–2·9 to 7·9)
Data are n/N (%) unless otherwise specified. *Food allergy was confirmed by oral food challenge interpreted by a masked allergy nurse using PRACTALL criteria in 21 of 
70 participants, or using a validated algorithm adapted from the EAT trial interpreted by a masked expert allergy panel (MJC, NJ, MK, RJB) in 49 of 70.25 †Unadjusted relative 
risk and difference in risk reported for cow’s milk. The model including stratification variables did not converge. ‡≥3 mm skin prick test to fresh milk, raw egg white, 
or commercial peanut extract. §Adjusted difference in risk and relative risk is not presented for individual allergens (specified in statistical analysis plan that between-group 
estimates would only be calculated for allergens grouped together). Allergic sensitisation to individual allergens tested is presented in the appendix (p 59).  ¶≥3 mm skin 
prick test to at least one of commercial grass pollen, cat dander, or dust mite extract.
Table 3: Secondary outcomes of confirmed food allergy, sensitisation to common food allergens, allergic rhinitis, and wheezing at age 2 years
Emollient 
group
Control group Unadjusted difference 
in means (95% CI)
CHU-9D at age 2 years* 0·935 (0·070) 0·934 (0·066) 0·001 (–0·007 to 0·009)
EQ-5D-5L parent health-related quality of 
life at baseline†
0·856 (0·151) 0·852 (0·158) ··
EQ-5D-5L parent health-related quality of 
life at age 2 years‡
0·921 (0·142) 0·919 (0·130) 0·002 (–0·013 to 0·018)
Data are mean (SD) unless otherwise specified. CHU-9D scores range from 0·33 to 1, with higher scores indicating 
better quality of life. EQ-5D-5L scores range from –0·594 to 1, with higher scores indicating better quality of life. 
Of those with data at baseline and age 2 years, 95% were completed by the same responder. The baseline EQ-5D-5L 
questionnaire was sent to parents in the post shortly after randomisation. CHU-9D=Child Health Utility-9 Dimensions. 
*n=573 in the emollient group and n=591 in the control group. †n=496 in both the emollient group and the control 
group. ‡n=573 in the emollient group and n=592 in the control group.
Table 4: Secondary outcome of quality of life
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formulation—for example, one containing ingredients 
such as ceramides and pH modulators—because when 
the barrier enhancement for eczema prevention (BEEP) 
trial was designed, they were not generally available and 
had a much higher purchase cost. However, a more 
sophisticated emollient formulation might potentially 
have a protective effect.
Limitations of the study include a low uptake of the 
oral food challenges due to several factors. Skin prick 
tests and oral food challenges were added to the trial 
once it was underway, so parents were unaware these 
tests would be offered when they decided to take part. 
Added to this, many parents were unwilling or unable to 
travel to the oral food challenge centres, mainly because 
they had no concern about food allergy in their child or 
their child had a previously established clinical diagnosis 
of food allergy. There is also significant uncertainty 
about the food allergy outcomes, which is not surprising 
as the study was powered to detect plausible changes in 
eczema rather than food allergy, which has a much 
lower incidence. A further limitation was the lower 
than expected response to interim questionnaires 
through which adherence was assessed.
The lack of benefit of emollients for prevention of 
eczema seen in this study was unexpected, particularly 
when considering the strong signal observed in the 
previously published pilot trials, and has major 
implications for the primary prevention of atopic eczema 
and other diseases.13,14 Adherence to the advice to apply 
emollients once a day might not have been sufficiently 
high enough to have an effect, or insufficient quantities 
might have been used during each application. Applying 
emollients all over the body daily for the first 12 months 
of life can be difficult to maintain for busy parents of 
healthy babies. However, data for those who completed 
questionnaires in which parents were asked about 
adherence to emollient use since the previous question-
naire showed that adherence was greater than 80% 
during the first 6 months, which was within our 
anticipated range, with most parents reporting applying 
emollient to the whole body. These adherence figures 
were similar to those seen in our pilot study.13 Although 
adherence decreased to 74% for months 6–12, this was a 
pragmatic study in which parents had little contact with 
the research team, reflecting how such a prevention 
strategy might be delivered in practice. Additionally, this 
reduction in emollient use was expected because of 
increased difficulty in regularly applying emollient to 
infants as they become more mobile as well as general 
parental fatigue with regards to the routine. There was a 
small amount of emollient use in the control group in 
those without any diagnosis of eczema, which could have 
partially masked any differences between the two groups. 
Emollients might have to be applied multiple times per 
day to exert a protective effect, or intervention for longer 
than a year might be required, but a more demanding 
schedule is more difficult to maintain or could be 
unacceptable to parents. Although the median duration 
between birth and start of emollient use was only 
11 days, even earlier intervention might be required with 
emollient therapy started closer to birth. The provision of 
skin care advice to parents in both groups was unlikely to 
have altered any effect of the emollient, since the advice 
was based on best practice skin-care advice in the UK and 
was identical to that used in the pilot trial in which a 
difference between groups was observed. However, 
awareness of the importance of using better formulated 
wash products has increased in recent years.13
Although there was no significant difference in 
occurrence of food allergy between the two groups, any 
degree of increase in the emollient group was unexpected. 
The non-significant association between emollient inter-
ven tion and increased food allergy was seen across 
several different measures, including objective tests of 
skin sensitisation. An increase in food allergy is plausible, 
through enhanced transfer and uptake of food antigens 
by emollient application, leading to epicutaneous sensi-
tisation.31 An ongoing prospective individual patient data 
meta-analysis32 of at least nine similar studies including 
the PEBBLES trial (NCT03667651) and the PreventADALL 
trial33 will provide more evidence on any association 
between use of emollients from birth and the risk of 
developing food allergy. The evidence for increased skin 
infections with emollients was stronger and could be due 
to increased inoculation of pathogens on the infant skin 
during application of emollients,34 disturbance of the 
skin microbiome, or emollients making the skin more 
adhesive to bacteria.
Understanding of the properties of the barrier function 
of the skin in early life has increased and it is possible 
that other approaches to skin barrier enhancement based 
on new knowledge might have a preventive effect. These 
approaches might include using newly developed 
emollients with enhanced skin barrier properties, or a 
complex intervention that includes additional stringent 
measures such as low pH cleansers, infrequent washing, 
or softened water. Future studies of new candidate 
emollients or more burdensome skin-care regimens will 
first need to ensure acceptability to parents and consider 
the inclusion of behavioural support to ensure adherence 
for prolonged periods.
Our study does not support the use of emollients for 
preventing eczema in high-risk infants, a finding 
supported by PreventADALL, another large trial using a 
skin barrier enhancing intervention.33 Our data relate 
only to prevention of eczema and do not directly 
challenge the practice of using emollients as first-line 
treatment for eczema.35
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